Extracellular vesicles derived from human ES-MSCs protect retinal ganglion cells and preserve retinal function in a rodent model of optic nerve injury.
Cis P- tau
Extracellular vesicle
Human embryonic stem cells
Mesenchymal stem cells
Optic nerve crush
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
27 05 2020
27 05 2020
Historique:
received:
29
10
2019
accepted:
03
05
2020
revised:
10
04
2020
entrez:
29
5
2020
pubmed:
29
5
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Retinal and/or optic nerve injury is one of the leading causes of blindness due to retinal ganglion cell (RGC) degeneration. There have been extensive efforts to suppress this neurodegeneration. Various somatic tissue-derived mesenchymal stem cells (MSCs) demonstrated significant neuroprotective and axogenic effects on RGCs. An alternative source of MSCs could be human embryonic stem cells (ES-MSCs), which proliferate faster, express lower levels of inflammatory cytokines, and are capable of immune modulation. It has been demonstrated that MSCs secrete factors or extracellular vesicles that may heal the injury. However, possible therapeutic effects and underlying mechanism of human ES-MSC extracellular vesicles (EVs) on optic nerve injury have not been assessed. EVs were isolated from human ES-MSCs. Then, ES-MSC EV was applied to an optic nerve crush (ONC) mouse model. Immunohistofluorescence, retro- and anterograde tracing of RGCs, Western blot, tauopathy in RGCs, and function assessments were performed during 2-month post-treatment to evaluate ONC improvement and underlying mechanism of human ES-MSC EV in in vivo. We found that the ES-MSC EV significantly improved Brn3a+ RGCs survival and retro- and anterograde tracing of RGCs, while preventing retinal nerve fiber layer (RNFL) degenerative thinning compared to the vehicle group. The EVs also significantly promoted GAP43+ axon counts in the optic nerve and improved cognitive visual behavior. Furthermore, cis p-tau, a central mediator of neurodegeneration in the injured RGCs, is detectable after the ONC at the early stages demonstrated tauopathy in RGCs. Notably, after EV treatment cis p-tau was downregulated. Our findings propose that human ES-MSC EVs, as an off-the-shelf and cell-free product, may have profound clinical implications in treating injured RGCs and degenerative ocular disease. Moreover, the possible mechanisms of human ES-MSC EV are related to the rescue of tauopathy process of RGC degeneration.
Sections du résumé
BACKGROUND
Retinal and/or optic nerve injury is one of the leading causes of blindness due to retinal ganglion cell (RGC) degeneration. There have been extensive efforts to suppress this neurodegeneration. Various somatic tissue-derived mesenchymal stem cells (MSCs) demonstrated significant neuroprotective and axogenic effects on RGCs. An alternative source of MSCs could be human embryonic stem cells (ES-MSCs), which proliferate faster, express lower levels of inflammatory cytokines, and are capable of immune modulation. It has been demonstrated that MSCs secrete factors or extracellular vesicles that may heal the injury. However, possible therapeutic effects and underlying mechanism of human ES-MSC extracellular vesicles (EVs) on optic nerve injury have not been assessed.
METHODS
EVs were isolated from human ES-MSCs. Then, ES-MSC EV was applied to an optic nerve crush (ONC) mouse model. Immunohistofluorescence, retro- and anterograde tracing of RGCs, Western blot, tauopathy in RGCs, and function assessments were performed during 2-month post-treatment to evaluate ONC improvement and underlying mechanism of human ES-MSC EV in in vivo.
RESULTS
We found that the ES-MSC EV significantly improved Brn3a+ RGCs survival and retro- and anterograde tracing of RGCs, while preventing retinal nerve fiber layer (RNFL) degenerative thinning compared to the vehicle group. The EVs also significantly promoted GAP43+ axon counts in the optic nerve and improved cognitive visual behavior. Furthermore, cis p-tau, a central mediator of neurodegeneration in the injured RGCs, is detectable after the ONC at the early stages demonstrated tauopathy in RGCs. Notably, after EV treatment cis p-tau was downregulated.
CONCLUSIONS
Our findings propose that human ES-MSC EVs, as an off-the-shelf and cell-free product, may have profound clinical implications in treating injured RGCs and degenerative ocular disease. Moreover, the possible mechanisms of human ES-MSC EV are related to the rescue of tauopathy process of RGC degeneration.
Identifiants
pubmed: 32460894
doi: 10.1186/s13287-020-01702-x
pii: 10.1186/s13287-020-01702-x
pmc: PMC7251703
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
203Références
Cytotherapy. 2015 May;17(5):543-59
pubmed: 25618560
Arthritis Res Ther. 2016 Apr 01;18:77
pubmed: 27036118
Nature. 2015 Jul 23;523(7561):431-436
pubmed: 26176913
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(13):5473-5480
pubmed: 30452601
J Tissue Eng Regen Med. 2019 Sep;13(9):1738-1755
pubmed: 31216380
Cytotherapy. 2016 Apr;18(4):487-96
pubmed: 26897559
Ocul Surf. 2019 Apr;17(2):198-207
pubmed: 30695735
Transl Psychiatry. 2017 Jan 31;7(1):e1020
pubmed: 28140402
Sci Rep. 2015 Dec 02;5:17685
pubmed: 26628350
J Alzheimers Dis. 2017;59(2):743-751
pubmed: 28671129
Stem Cell Res Ther. 2019 Apr 17;10(1):121
pubmed: 30995945
Stem Cell Reports. 2014 Jun 06;3(1):115-30
pubmed: 25068126
Regen Med. 2016 Jan;11(1):33-43
pubmed: 26387424
J Neurosci. 2013 Sep 11;33(37):14816-24
pubmed: 24027282
Nature. 2017 Jul 13;547(7662):185-190
pubmed: 28678775
Eye (Lond). 2017 Feb;31(2):218-224
pubmed: 28085136
J Cell Physiol. 2018 Dec;233(12):9330-9344
pubmed: 29266258
J Cell Biochem. 2016 Dec;117(12):2844-2853
pubmed: 27167148
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):702-714
pubmed: 29392316
MethodsX. 2015 Sep 10;2:360-7
pubmed: 26543819
Sci Rep. 2016 Sep 30;6:34562
pubmed: 27686625
ACS Appl Mater Interfaces. 2019 Oct 16;11(41):37421-37433
pubmed: 31525863
Cell. 2012 Mar 30;149(1):232-44
pubmed: 22464332
Cell Transplant. 2012;21(10):2225-39
pubmed: 22776744
J Chem Neuroanat. 2019 Mar;96:134-139
pubmed: 30639447
Dev Growth Differ. 2006 Feb;48(2):117-28
pubmed: 16512855
Cell Transplant. 2013;22(10):1785-99
pubmed: 23394436
Stem Cells Transl Med. 2017 Apr;6(4):1273-1285
pubmed: 28198592
Int J Mol Sci. 2019 Apr 10;20(7):
pubmed: 30974904
Nat Commun. 2017 Oct 17;8(1):1000
pubmed: 29042562
Clin Interv Aging. 2015 Feb 16;10:487-90
pubmed: 25733825
Mol Med Rep. 2018 Feb;17(2):2529-2534
pubmed: 29207059
ACS Chem Neurosci. 2019 Mar 20;10(3):1214-1221
pubmed: 30644730
Brain. 2014 Feb;137(Pt 2):503-19
pubmed: 24176979
Methods Mol Biol. 2019;1834:367-381
pubmed: 30324455
Immunol Lett. 2015 Dec;168(2):154-8
pubmed: 26086886
Stem Cells. 2018 Jun;36(6):844-855
pubmed: 29476565
Int J Ophthalmol. 2018 Apr 18;11(4):559-566
pubmed: 29675371
Sci Rep. 2017 Jun 28;7(1):4323
pubmed: 28659587
Neuroscience. 2016 Apr 21;320:129-39
pubmed: 26851773
Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9149-54
pubmed: 22615390
Science. 2018 Jun 15;360(6394):1242-1246
pubmed: 29748322
Cytotherapy. 2016 Mar;18(3):413-22
pubmed: 26857231
Sci Rep. 2015 Jun 09;5:11235
pubmed: 26057572
PLoS One. 2013;8(1):e55319
pubmed: 23383153
Biochem Biophys Res Commun. 2006 Jun 16;344(4):1071-9
pubmed: 16643846
Stem Cells Dev. 2016 Dec 15;25(24):1898-1908
pubmed: 27676103
PLoS Biol. 2007 Sep;5(9):e241
pubmed: 17803360
Stem Cells. 2019 May;37(5):572-581
pubmed: 30561809
Sci Rep. 2015 Mar 30;5:9322
pubmed: 25818803
Stem Cell Res Ther. 2015 Nov 11;6:212
pubmed: 26560482
Mol Ther. 2015 May;23(5):812-823
pubmed: 25868399
Neurobiol Dis. 2015 Apr;76:13-23
pubmed: 25576397
Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2051-9
pubmed: 19933193
Invest Ophthalmol Vis Sci. 2013 Nov 15;54(12):7544-56
pubmed: 24150755
Stem Cell Res. 2015 May;14(3):243-57
pubmed: 25752437
Mol Neurobiol. 2017 May;54(4):2659-2673
pubmed: 26993303
Stem Cell Rev Rep. 2017 Oct;13(5):598-602
pubmed: 28643176
Regen Med. 2014;9(4):453-65
pubmed: 25159063
Curr Eye Res. 2017 Oct;42(10):1358-1367
pubmed: 28636406
Front Pharmacol. 2017 Jul 28;8:501
pubmed: 28804458